← All trials
NCT07217886
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 16, 2025
- Primary completion
- Jun 5, 2026
- Completion date
- Jun 5, 2026
- First posted
- Oct 17, 2025
- Last posted
- Oct 30, 2025
- Enrollment
- 40
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ShionogiLead sponsor
- Department of Health and Human ServicesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.